The Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of IL-23 Signaling in Peripheral and Axial Spondyloarthritis

Launched by INSTITUT PASTEUR · Mar 11, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the role of a substance called IL-23 in patients with a condition known as spondyloarthritis, which can cause inflammation in the spine and joints. Researchers want to learn more about how patients respond to specific treatments that target IL-23. The study is taking place in two hospitals in Paris and is open to adults over 18 who have been diagnosed with active spondyloarthritis, meaning they experience significant pain and inflammation. Participants may be new to biological therapies or have been treated with one before, but they must meet specific health criteria to join.

If you are eligible and decide to participate, you will be closely monitored by healthcare professionals during the study. This involves regular check-ups and assessments to understand how well the treatment is working for you. It's important to note that the trial is currently recruiting participants, and your involvement will help advance our understanding of spondyloarthritis and improve future treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age : Adults (\>18 years)
• • Satisfying ASAS diagnostic criteria for SpA
• • Patient has active disease, defined by the presence of active synovitis, tendinitis, or dactylitis or significant inflammatory pain of the spine, judged by the examining clinician to be due to SpA.
• • Informed consent signed
• • Beneficiary of health insurance, except for the AME
• • Only for patients of Group 1 • Patient is naïve to biological therapies
• • Only for patients of Group 2
• • Patient is affected by peripheral SpA (ASAS criteria) or psoriatic arthritis, with inflammation of peripheral joints
• • Patient requires aspiration, as part of standard care
• Non inclusion criteria:
• • Patient is minor
• • Patient is pregnant or breastfeeding
• • Patient is immunocompromised
• • Patient has received biological therapy with 2 or more biologics
• • Patient is receiving corticosteroid treatment \> 10 mg per day
• • Patient is under legal protection, curators, guardianship
• • Patient refuses consent
• • Previous history of alcoholism, drug addiction, psychological problems, severe concomitant conditions that could invalidate the patient's consent or limit the patient's compliance to the treatment protocol.
• • Beneficiary of the AME
• • Only for group 1
• • • Patient has received biological therapy